澳大利亞昆士蘭大學許志平教授做客第287期化苑講壇
報告題目：Inorganic nanoparticles as efficient platforms for cancer therapy and diagnosis
報 告 人 ：許志平教授
報告時間：2017年9月30日（周六）上午10:00
報告地點：化學樓二樓一號會議室
邀 請 人 ：吳鈺周教授
報告人簡介：
Prof. Xu received his Bachelor’s degree in the University of Science & Technology of China in 1988. He also got his Master’s degree in 1991 in the same university. And then, he went to the National University of Singapore to get another Master’s degree in 1997 and received his PhD in 1997. Prof. Xu became the postdoctoral research scientist in the University of North Texas during 2001-2003. Now, Prof. Xu is the UQ VC senior research fellow in the Australian Institute for Bioengineering and Nanotechnology, UQ. Prof. Xu has published 200 papers and his total citation has reached to 8000(Google Scholar). Prof. Xu’s major research interests are mainly concentrated in five aspects:1) Control prepration of clay nanomaterials, calcium phosphate nanoparticles, quantum dots, nanoemulsion, liposome, Au/Ag nanoparticles, upconversion nanoparticles and biosensors; 2) Delivery of drugs and gene to treat cancers and other diseases; 3) Developemnt of nanoadjuvants for enhanced immunisation for human health and animal health; 4) Imaging and diagnosis of normal and disease tissues (in particular tumour tissues); 5) Development of nanotechnology for crop protection and weed growth control.
報告內容：
Prof. Xu will first introduce two types of inorganic nanoparticles, i.e. layered double hydroxide (LDH) and lipid-coated calcium phosphate (LCP) nanoparticles, and then demonstrate their high potential as the drug/gene delivery platforms. Prof. Xu will present a few examples to show efficient co-delivery of functional small interfering RNA (siRNA) and anti-cancer drug to cancer cells for the synergic inhibition. Prof. Xu will also talk about our recent results for target delivery of siRNA to treat cancers.
In the second part, Prof. Xu will present our recent research using clay nanoparticles as vaccine adjuvants to promote higher and long-term immune responses against cancer and bacteria. We have noted that LDH is able to readily load model antigen ovalbumin (OVA) and the toll-like receptor ligand CpG together, promote higher levels of specific antibodies, and modulate the immune response from Th2 bias towards the preferred polarity Th1 for anti-cancer purpose. They have found that LDH and hectorite (HEC) nanoparticles as adjuvants to promote stronger and long-lasting immune responses against the infectious bacteria.
In the final part, Prof. Xu will demonstrate the capability of inorganic nanoparticles as positron emission tomography (PET) and magnetic resonance imaging (MRI) contrast agents for cancer imaging and detection.
